Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals' stock price has experienced significant movements over the past six months. As of January 12, 2026, the share price was $510.53, a 68.10% increase over the past year. Key events impacting the stock include strong Rezdiffra sales and launch momentum, with Q2 2025 net sales at $212.8 million and Q3 2025 net sales reaching $287.3 million. The company reported ($5.08) EPS for Q3 2025, missing analysts' consensus estimates. Analyst ratings varied, with Goldman Sachs and Truist Securities reiterating "Buy" ratings, while Wolfe Research downgraded Madrigal to "Peerperform." A director, Paul Friedman, sold 24,520 shares in January 2026. Madrigal announced an exclusive global license from Pfizer for ervogastat and secured a new U.S. patent for Rezdiffra extending its protection until February 4, 2045. The approval of Novo Nordisk's Wegovy introduced a significant competitor.

Significant demand seasonality for Madrigal Pharmaceuticals' products and services is unlikely, as Rezdiffra treats a chronic liver disease (MASH). The available information does not indicate any specific seasonal patterns in the demand for MASH treatments. The nature of a chronic condition typically leads to a more consistent demand profile throughout the year.

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Their flagship product, Rezdiffra (resmetirom), is the first FDA-approved medication for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, used with diet and exercise. Madrigal is also evaluating Rezdiffra for compensated MASH cirrhosis and has other pipeline products, including MGL-3196, ervogastat, and an oral GLP-1 development candidate.

Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania, United States. Rezdiffra was commercially launched in the United States in April 2024. The company received conditional marketing authorization for Rezdiffra in the European Union in August 2025 and plans to launch the product in Germany in the second half of 2025.

Madrigal Pharmaceuticals has a strong reputation due to its scientific rigor and commitment to patient well-being, particularly through the development of Rezdiffra. The company's reputation has been significantly bolstered by being the first to secure regulatory approval for a MASH treatment, Rezdiffra, which is generating substantial product revenue. The successful launch of Rezdiffra has been described as one of the most successful specialty drug launches of the past decade. The primary challenge mentioned is the intensifying competition from GLP-1 drugs and emerging FGF21 inhibitors targeting the same market.

Madrigal Pharmaceuticals, Inc. has a highly concentrated ownership structure, predominantly held by institutional investors. Institutions hold 83.7% of the company, with major holders including Baker Bros. Advisors Lp, RTW Investments, Lp, and Paulson & Co. Inc. Individual insiders hold 4.44% of the shares, with Bruce Kovner being the largest individual shareholder.